Q2 Solutions and MindX Sciences Inc., a company that works to improve lives through empowering precision medicine approaches to mental health, today announced a partnership, where Q2 Solutions will be conducting genomics laboratory testing services for MindX Sciences blood tests.
MORRISVILLE, N.C., June 3, 2021 /PRNewswire/ -- Q2 Solutions and MindX Sciences Inc., a company that works to improve lives through empowering precision medicine approaches to mental health, today announced a partnership, where Q2 Solutions will be conducting genomics laboratory testing services for MindX Sciences blood tests. Initial tests offered by MindX will include mood disorders, such as depression and bipolar disorder, as well as pain, post-traumatic stress disorder (PTSD), suicidality, memory disorders, and longevity. Initial tests offered by MindX will include mood disorders, such as depression and bipolar disorder, pain, PTSD, and suicidality One in four people face a mental health challenge during their lifetime and over 20% of the population suffers from chronic pain. In addition, psychiatric impacts of the COVID-19 global pandemic have highlighted the need for improved testing for people living with mental health issues. Laboratory tests have been used extensively in other fields of medicine and this opportunity allows for the same in the field of psychiatry. “This collaboration presents a unique application of our whole transcriptome analysis services and we look forward to leveraging our strengths in genomic testing to help unmet patient needs in the field of psychiatry,” said Kellie Yarnell, VP, Genomic Laboratories, Q2 Solutions. “This is the culmination of over 15 years of academic research, that is now translated to clinical practice, to help improve and save lives by enabling doctors and pharmaceutical companies to do a better job.”, said Dr. Alexander B. Niculescu, Founder and Chairman, MindX Sciences. “We are now entering the era of precision medicine in psychiatry, similar to what our colleagues in cancer and other fields are already doing. These tests will help provide objective information to doctors, as well as provide them with suggestions for medications that match the patient, and an ability to monitor response to treatment. Ultimately, the goal is to prevent future episodes from occurring, so people can have happier, more productive, and longer lives.” About MindX Sciences, Inc. CONTACT: Chris Wright, +317 289 4730, info@mindxsciences.com View original content:http://www.prnewswire.com/news-releases/q2-solutions-partners-with-mindx-sciences-inc-301305194.html SOURCE MindX Sciences |